Lactococcus lactis harbouring Ara h 2.02 alleviates allergen-specific Th2-associated responses in sensitized mice
To study the prophylactic effect of recombinant Lactococcus lactis (rLl) harbouring Ara h 2.02 peanut allergen, in sensitized and challenged mice.
Methods and Results
Ara h 2.02 cDNA was cloned into pNZ8048 for heterologous expression in L. lactis. The purified recombinant allergen showed IgE binding comparable with native Ara h 2. Balb/c mice were fed with either recombinant (rLl), nonrecombinant L. lactis (Ll) or NaHCO3 (Sham) prior to sensitization and challenged with rAra h 2.02, whereas the baseline group was only fed with Ll. Allergen-specific immunoglobulin and splenocyte cytokines responses were determined for each mouse. Mice fed with either Ll or rLl showed significant alleviation of IgE and IgG1 compared to the Sham group. Despite no significant decrease in Th2 (IL-4, IL-13, IL-6) or increase in Th1 (IFN-γ) cytokines, both groups showed lower IL-10 level, while the IL-4 : IFN-γ ratio was significantly lower for rLl compared to Ll group.
Oral administration of rLl harbouring Ara h 2.02 demonstrated alleviation of Th2-associated responses in allergen-challenged mice and a possible added allergen-specific prophylactic effect.
Significance and Impact of the Study
Ara h 2.02 coupled with the intrinsic properties of probiotic L. lactis as a delivery vehicle can be explored for the development of a commercially scalable vaccine.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2005) Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 35, 539– 546.
- 2014) Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergen. J Allergy Clin Immunol 133, 621– 631.
- 2003) Peanut allergy: an overview. CMAJ 168, 1279– 1285.
- 2011) Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 41, 1273– 1281.
- 2014) Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 383, 1297– 1304.
- 2003) Interleukin-10 therapy—review of a new approach. Pharmacol Rev 55, 241– 269.
- 2008) Nisin inducible production of listeriolysin O in Lactococcus lactis NZ9000. Microb Cell Fact 7, 24.
- 2011) Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 10, S4.
- 2001) Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 108, 516– 520.
- 2011) Use of the usp45 lactococcal secretion signal sequence to drive the secretion and functional expression of enterococcal bacteriocins in Lactococcus lactis. Appl Microbiol Biotechnol 89, 131– 143.
- 2014) Peanut allergy prevalence among school-age children in a US cohort not selected for any disease. J Allergy Clin Immunol 134, 753– 755.
- 2014) Expanding the recombinant protein quality in Lactococcus lactis. Microb Cell Fact 13, 167.
- 2003) Isolation and characterization of two complete Ara h 2 isoform cDNA. Int Arch Allergy Immunol 131, 14– 18.
- 2005) Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 115, 3– 12.
- 2007) The changing face of food hypersensitivity in an Asian community. Clin Exp Allergy 37, 1055– 1061.
- 1991) Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol Rev 123, 189– 207.
- 2003) Ability of Lactococcus lactis to export viral capsid antigens: a crucial step for development of live vaccines. Appl Environ Microb 69, 7281– 7288.
- 1999) Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 65, 4881– 4886.
- 2016) Effect of avoidance on peanut allergy after early peanut consumption. N Engl J Med 374, 1435– 1443.
- 2005) Oral tolerance. Immunol Rev 206, 232– 259.
- 2007) Production of recombinant peanut allergen Ara h 2 using Lactococcus lactis. Microb Cell Fact 6, 28.
- 2004) Isoforms of the major peanut allergen Ara h 2: IgE binding in children with peanut allergy. Int Arch Allergy Immunol 135, 101– 107.
- 1999) Integrating signals from IFN-γ and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a. J Immunol 163, 4175.
- 2007) Efficient production and secretion of bovine b-lactoglobulin by Lactobacillus casei. Microb Cell Fact 6, 12.
- 2016) Single B-cell deconvolution of peanut-specific antibody responses in allergic patients. J Allergy Clin Immunol 137, 157– 167.
- 1989) High-frequency transformation, by electroporation, of Lactococcus lactis subsp. cremoris grown with glycine in osmotically stabilized media. Appl Environ Microbiol 55, 3119– 3123.
- 2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30, 531– 564.
- 2013) Oral immunotherapy for food allergy: towards a new horizon. Allergy Asthma Immunol Res 5, 3– 15.
- 1993) Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis, requirement of expression of the nisA and nisI genes for development of immunity. Eur J Biochem 216, 281– 291.
- 2003) Lactococcus lactis as host for overproduction of functional membrane proteins. Biochim Biophys Acta 1610, 97– 108.
- 2013) Food allergy in Asia: how does it compare? Asia Pac Allergy 3, 3– 14.
- 2003) High-yield expression in Escherichia coli, purification, and characterization of properly folded major peanut allergen Ara h 2. Protein Expr and Purif 31, 250– 259.
- 2016) Expression of a codon-optimised recombinant Ara h 2.02 peanut allergen in Escherichia coli. Appl Microbiol Biotechnol 100, 661– 671.
- 2009) The effects of heat-killed wild-type Lactobacillus casei Shirota on allergic immune responses in an allergy mouse model. Int Arch Allergy Immunol 148, 297– 304.
- 2001) IgE-binding properties of recombinant food allergens. Internet Symp Food Allerg 3, 1– 36.
- 1997) Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 185, 415– 428.
- 2012) Immune regulatory function of B cells. Annu Rev Immunol 30, 221– 241.
- 2005) 10 Years of the Nisin-controlled Gene Expression System (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68, 705– 717.
- 1996) Production of human tumor necrosis factor alpha interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 64, 5403– 5405.
- 2015) Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects. J Allergy Clin Immunol 136, 125– 134.e12.
- 2005) New therapeutic strategy for combating the increasing burden of allergic disease: probiotics – a Nutrition, Allergy, Mucosal Immunology And Intestinal Microbiota (NAMI) Research Group report. J Allergy Clin Immunol 116, 31– 37.
- 2014) Modulation of peanut-induced allergic immune responses by oral lactic acid bacteria-based vaccines in mice. Appl Microbiol Biotechnol 98, 6353– 6364.
- 2004) Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 113, 395– 400.
- 1988) Enhancement of host resistance against Listeria infection by Lactobacillus casei: efficacy of cell wall preparation of Lactobacillus casei. Microbiol Immunol 32, 1189– 1200.
- 2013) Recent advances in the diagnosis and therapy of peanut allergy. Expert Rev Clin Immunol 9, 551– 560.
- 2010) A population-based questionnaire survey on the prevalence of peanut, tree nut and shellfish allergy in 2 Asian populations. J Allergy Clin Immunol 126, 324– 331.
- 2016) Oral vaccine of Lactococcus lactis harbouring pandemic H1N1 2009 haemagglutinin1 and nisP anchor fusion protein elevates anti-HA1sIgA levels in mice. Biotechnol Lett 38, 793– 799.
- 2012) Functional expression of an orchid fragrance gene in Lactococcus lactis. Int J Mol Sci 13, 1582– 1597.
- 2012) Effect of signal peptides on the secretion of b-cyclodextrin glucanotransferase in Lactococcus lactis NZ9000. J Mol Microbiol Biotechnol 22, 361– 372.
- 2015) Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol 135, 737– 744.
- 2006) Serum opacity factor promotes group A streptococcal epithelial cell invasion and virulence. Mol Microbiol 62, 15– 25.
- 1993) Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 61, 4167– 4172.
- 2003) Practical considerations in refolding proteins from inclusion bodies. Protein Expr Purif 28, 1– 8.
- 2011) A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127, 654– 660.
- 2017) The role of regulatory B cells in allergen immunotherapy. Curr Opin Allergy Clin Immunol 17, 447– 452.
- 2010) Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. Allergy 65, 103– 108.
- 2011) Food allergy. J Clin Invest 121, 827– 835.
- 2008) Clinical immunology review series: an approach to the use of the immunology laboratory in the diagnosis of clinical allergy. Clin Exp Immunol 153, 10– 18.
- 2007) IL-10-producing type 1 regulatory T cells and allergy. Cell Mol Immunol 4, 269– 275.
- 2015) Clinical manifestation and sensitization of allergic children from Malaysia. Asia Pac Allergy 5, 78– 83.
- 2014) Refolding techniques for recovering biologically active recombinant proteins from inclusion bodies. Biomolecules 4, 235– 251.